ResearcherUniversity of North Carolina at Chapel HillNo recent work listed

Mengzhe Wang

ORCID-verified (high confidence, 0.95), identity_conf@1As of 8 November 2026

Matched on ORCID iD 0000-0003-4654-6845; OpenAlex author ID A5070297217. Sources: OpenAlex.

Their work

Papers: 2 (first author 1, last author 0)
Trials: 0
Grants: 0
Labs led: 0
Collaborators: 3

Papers, trials and grants by year

2017: 1 paper · 2018: 1 paper

Papers 2

Development of [18F]AlF-NOTA-NT as PET Agents of Neurotensin Receptor-1 Positive Pancreatic Cancer. Co-author DOI 10.1021/acs.molpharmaceut.8b00192 ↗
Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. First author DOI 10.1007/s00726-017-2430-5 ↗

Closest collaborators

The 3 strongest of 3 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

Zibo Li · 2 shared papers, 2017–2018 · strength 0.15
- Paper Development of [18F]AlF-NOTA-NT as PET Agents of Neurotensin Receptor-1 Positive Pancreatic Cancer. DOI 10.1021/acs.molpharmaceut.8b00192 ↗
- Paper Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. DOI 10.1007/s00726-017-2430-5 ↗
Hui Wang · 2 shared papers, 2017–2018 · strength 0.15
- Paper Development of [18F]AlF-NOTA-NT as PET Agents of Neurotensin Receptor-1 Positive Pancreatic Cancer. DOI 10.1021/acs.molpharmaceut.8b00192 ↗
- Paper Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. DOI 10.1007/s00726-017-2430-5 ↗
Xiaoqin Yin · 1 shared paper, 2017 · strength 0.07
- Paper Evaluation of neurotensin receptor 1 as a potential imaging target in pancreatic ductal adenocarcinoma. DOI 10.1007/s00726-017-2430-5 ↗

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.